Honduras, which is located in Central America, has been endemic for malaria for many recorded centuries. Fortunately, because of national control efforts, the country has recently attained the goal of reducing the incidence of malaria by at least 75% by 2015 ([@B8], [@B14]). However, more than 5,000 cases of malaria are still being reported annually; the majority of these cases are caused by *Plasmodium vivax* and 12-15% are due to *Plasmodium falciparum*([@B8]).

In Central America, falciparum malaria is treated with chloroquine (CQ) because no instances of drug resistance have yet been reported in the region ([@B4], [@B6]). A potential threat to the current malaria control success in Honduras is that CQ-resistant *P. falciparum* strains have already been identified in neighbouring regions over the past several years ([@B2]); more recently, a resistant phenotype (CVIET) was detected in two of the 53 isolates obtained from the border region of Nicaragua ([@B11]). It is widely recognised that global commerce and international travel provide opportunities for the spread of infectious pathogens across international borders.

CQ resistance is conferred by mutations in the CQ transporter gene (*pfcrt*). A five-amino acid sequence located in positions 72-76 of this gene is the main determinant for CQ susceptibility vs. resistance. In addition to the CQ susceptible wild type strain (CVMNK), at least four mutant lineages have been associated with a resistant phenotype, namely CVIET, CVIDT, SVMNT and CVMNT ([@B12]). Monitoring genotype changes in circulating parasites could be useful as an effective early warning system that can help develop the timely response mechanisms required to avert the further spread of the resistant strains. This might prove instrumental in preventing the widespread distribution of resistant strains, as observed decades ago on other continents ([@B15], [@B7], [@B9], [@B13]).

For this reason, a surveillance program has been implemented in Honduras since 2010 to monitor for drug resistance in circulating *P. falciparum* isolates ([@B8]).

A total of 160 samples, from the same number of patients, collected between 2010-2013 were analysed (68 in 2010, 28 in 2011 and 32 each in 2012 and 2013). The data from the 2010 samples have been published elsewhere ([@B6]). Blood samples were collected from febrile patients seeking medical attention at primary health centres across the country. Upon malaria diagnosis, patients were asked for consent to be included in the drug resistance surveillance program. Consenting patients provided a blood sample through a finger prick and the blood was blotted onto a paper filter. The 160 samples represented a randomised 10% of samples diagnosed as *P. falciparum*and received for quality control at the National Malaria Laboratory (NML) in Tegucigalpa, the capital city. These samples belonged to patients residing in six endemic departments in the country. Laboratory work was conducted at the Teasdale-Corti Laboratory (School of Microbiology) and the NML.

DNA was extracted using Chelex-100 (Bio-Rad Laboratories, Inc, USA) (de [@B1]). The microscopic diagnosis of the parasite species was confirmed through amplification of the 18Sr gene ([@B10]). The *P. falciparum pfcrt* gene was amplified using nested polymerase chain reaction (PCR) as previously described ([@B6]), based on the technique developed by [@B3]. Amplicons were observed on 1% et-br agarose gels. PCR products were purified according to the manufacturer's instructions (Promega) and sequenced at the Macrogen facilities (macrogenusa.com) using the primer 5'-TTTTTCCCTTGTCGACCTTAAC-3'. Chromas Pro and Mega5 software were used for sequence analysis. Positions 72-76 of *pfcrt* exon two were evaluated.

All of the samples (n = 160) collected during the four consecutive years of surveillance revealed the *pfcrt* "CVMNK" genotype in codons 72-76 that is associated with CQ susceptibility. This genetic approach supports the hypothesis that *P. falciparum* CQ resistant strains have neither emerged locally nor been introduced into the country. These findings indicate that CQ is still efficacious for the treatment of falciparum malaria in Honduras, which is congruent with the clinical experience described by local health care professionals and with the reports from the national health authorities.

Our findings are excellent news for the country and the Central American region, but they do not deny the potential for resistant strains emerging and being imported into the Honduran territory, as demonstrated by the detection of two isolates with the resistance allele CVIET in Nicaragua ([@B11]). Those isolates were recovered from the Nicaraguan North Atlantic Autonomous Region, which shares a relatively homogeneous parasite population with its neighbouring Honduran Moskitia region ([@B5]). In addition, to our knowledge, Honduran health officials have detected three cases of patients infected in Africa with resistant strains of *P. falciparum*(unpublished data); one of these patients died before he could receive proper treatment.

In conclusion, the monitoring of the circulating phenotypes and genotypes in the country is necessary to ensure Honduras's progress towards the elimination of malaria that could be halted by the development of drug-resistant parasites.
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